Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.77  0.01  0.36%   
About 54% of Lisata Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are impartial. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at finance.yahoo.com         
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreem...
Yahoo News
over two months ago at businesswire.com         
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combina...
businesswire News
over two months ago at benzinga.com         
Disposition of 26964 shares by Mazzo David J of Lisata Therapeutics at 2.93 subject to Rule 16b-3
benzinga news
over two months ago at finance.yahoo.com         
Sagimet Biosciences to Present at the H.C. Wainwright 8thAnnual MASH Virtual Conference and Announce...
Yahoo News
over two months ago at investors.com         
Top 1 percent Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover
Investors Business Daily at Macroaxis
over two months ago at simplywall.st         
Is Shanghai Junshi Biosciences Using Debt Sensibly?
Simply Wall St News at Macroaxis
over two months ago at seekingalpha.com         
IGM Biosciences to minimize spending on oncology candidates, appoints new CEO
seekingalpha News
over two months ago at investing.com         
Harmony Biosciences executive sells shares worth over 8,000
Investing News at Macroaxis
over two months ago at finance.yahoo.com         
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
Yahoo News
over two months ago at finance.yahoo.com         
Walden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney D...
Yahoo News
over two months ago at insidermonkey.com         
Is Avidity Biosciences, Inc. the Best Performing Long Term Stock in 2024?
insidermonkey News
over two months ago at accesswire.com         
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Shareholde...
news
over two months ago at zacks.com         
Pacific Biosciences of California Advances While Market Declines Some Information for Investors
zacks News
over two months ago at businesswire.com         
New Data at ASTRO 2024 Shows Castle Biosciences DecisionDx-SCC Test Provides More Precise Risk Strat...
businesswire News
over two months ago at accesswire.com         
Harmony Biosciences Holdings, Inc. Shareholders May Have Been Affected by Fraud - Levi Korsinsky Inv...
news
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Buying CFO Alan Fuhrman Acquires 9,500 Shares of Tyra Biosciences Inc
11/01/2024
2
Wellington Management Group LLP Acquires New Stake in MBX Biosciences Inc
11/08/2024
3
Xenetic Biosciences Third Quarter 2024 Earnings Misses Expectations
11/15/2024
4
Artelo Biosciences Stock Surges Amid Strong Buy Ratings
11/20/2024
5
After Leaping 47 percent Shanghai OPM Biosciences Co., Ltd. Shares Are Not Flying Under The Radar
11/21/2024
6
Aptose Biosciences Inc. Announces Pricing of 8 Million Public Offering
11/22/2024
7
Forte Biosciences to Host RD Day December 3, 2024
11/25/2024
8
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA
11/26/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators